Top news of July: OSA combination drug, COVID-19 diaphragm muscle weakness
Healio has compiled the most-read news in pulmonology posted in July.
Highlights include a study showing reduced obstructive sleep apnea severity with a combination of atomoxetine and oxybutynin taken for 1 month; a link between diaphragm muscle weakness and shortness of breath after COVID-19; declining cognition in older adults with OSA; men with HIV more frequently having sleep-disordered breathing than men without HIV; higher odds for asthma and wheezing with exercise in children with a type of food insecurity; and more.
Read these and other top stories in pulmonology below:
Obstructive sleep apnea combination drug safe, reduces disorder severity over 1 month
A combination of atomoxetine and oxybutynin taken for 30 days lowered baseline obstructive sleep apnea severity, according to results published in Annals of the American Thoracic Society. Read more.
Diaphragm muscle weakness linked to persistent shortness of breath following COVID-19
Fifteen months following COVID-19 hospitalization, both ventilated and nonventilated patients displayed diaphragm muscle weakness, according to results published in American Journal of Respiratory and Critical Care Medicine. Read more.
Obstructive sleep apnea linked to worsening cognition in older adults
Older adults who suffer with hypoxemia while sleeping showed decreased measures of cognition over a 5-year period, according to study results published in European Respiratory Journal. Read more.
Sleep-disordered breathing more frequent in men with vs. without HIV
When evaluating oxygen desaturation index scores with 4% desaturation, sleep-disordered breathing was found more often in men with vs. without HIV, according to study results published in CHEST. Read more.
Food insecurity raises odds for asthma, wheezing with exercise in children
Children living in a household that reportedly ran out of food faced heightened odds for asthma and signs of wheezing with exercise, according to research presented at the American Thoracic Society International Conference. Read more.
3-year wildfire smoke exposure raises all-cause, nonaccidental, neoplasm mortality risk
Risk for all-cause, nonaccidental and neoplasm mortality was heightened with exposure to elevated levels of wildfire-related fine particulate matter, according to study results published in Journal of Hazardous Materials. Read more.
FDA grants rare pediatric disease designation to neonatal lung therapy
The FDA has granted rare pediatric disease designation to vitamin A metabolic and reparative respiratory drugs manufactured by Advent Therapeutics to stop the development of bronchopulmonary dysplasia, according to a press release. Read more.
FDA issues two class I recalls involving ventilators
The FDA has issued class I recalls, the most serious kind, for two different ventilators from Draeger Medical and NOxBOX. Read more.
Q&A: Respiratory therapist discusses RSV vaccines, CDC recommendation
At this point in 2023, several advances have been made to protect individuals from respiratory syncytial virus. To learn more about these recent developments in RSV protection, as well as how to address vaccine hesitancy, Healio spoke with Mandy De Vries, MSc, RRT, RRT-NPS, respiratory therapist and director of education at the American Association for Respiratory Care. Read more.
Understanding, challenging racism in pulmonary function testing
By using race-specific equations when interpreting pulmonary function tests, racism and bias come to the surface, according to a presentation at the American Thoracic Society International Conference. Read more.